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Axillary treatment for patients with early
breast cancer and lymph node metastasis:
systematic review protocol
Amit Goyal1*, Lelia Duley2 and Apostolos Fakis3
Abstract
Background: For patients with early breast cancer and lymph node metastasis, axillary treatment is widely
recommended. This is either surgical removal of the axillary lymph nodes, or axillary radiotherapy. The rationale for
axillary treatment is that it will reduce the risk of recurrence in the axilla, and may improve survival. However, both
treatments are associated with adverse effects, such as lymphedema, pain and sensory loss, and are costly to the
health services and to patients. With improvements in adjuvant therapy, routine axillary treatment may no longer
offer any overall advantage.
Objectives: To assess the short and long term benefits and adverse effects of routine axillary treatment
(axillary lymph node clearance or axillary radiotherapy) for patients with lymph node positive early-stage breast cancer.
Methods/Design: Criteria for potentially eligibility for the study will be that the participants are men and women with
early breast cancer and lymph nodes with metastasis. The study compares either axillary treatment with no axillary
treatment, or axillary node clearance with axillary radiotherapy, and the study is a randomized trial. Primary outcomes
are axillary recurrence, disease-free and overall survival. Secondary outcomes include breast or chest wall recurrence,
distant metastasis, time to axillary recurrence, axillary recurrence-free survival, arm morbidity, quality of life and health
economic costs. The search strategy will include the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE
and WHO International Clinical Trials Registry Platform (ICTRP) search portal. Two independent reviewers will assess
studies for inclusion in the review, assess study quality and extract data. Characteristics of included studies will be
described. Meta-analysis will be conducted using ReVman software.
Comment: This review addresses an important clinical question, and results will inform clinical practice and health
care policy.
Background
Description of the condition
Breast cancer is the most frequent cancer affecting women
worldwide [1]. For example, in the UK more than 45,000
people are diagnosed with breast cancer each year and the
majority (80%) of these patients undergo surgical treat-
ment [2]. Patients with early-stage invasive breast cancer
undergo breast surgery, which could be lumpectomy (wide
local excision) or mastectomy. These patients also have
one or two lymph nodes (glands) removed from the axilla
(armpit) during this surgery to check if the cancer has
spread to the nodes; a procedure called sentinel node
biopsy (SNB). In around a quarter of patients, the cancer
has spread to the nodes. Current practice is that these
patients with cancer in the nodes undergo axillary treat-
ment, which is either surgical removal of the remaining
axillary nodes or axillary radiotherapy.
Description of the intervention
Axillary node clearance (ANC) is removal of all axillary
nodes in the armpit in patients found to have cancer
spread to lymph nodes (sentinel nodes) removed during
sentinel node biopsy. This is usually performed at a sec-
ond operation, which can be difficult due to scarring
from the first operation (sentinel node biopsy). A drain
is left in the armpit for a few days afterwards [3]. The
operation lasts one to two hours and requires a stay in
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hospital of up to five days. It delays the patient’s return
to day-to-day activities and paid work [4].
Axillary radiotherapy (ART) is radiation treatment of
the remaining axillary nodes. It is used instead of axillary
node clearance for some patients. The prescribed radi-
ation dose is given on a daily basis, five days a week for
three to five weeks. Axillary radiotherapy is offered in
some specialist centres, and patients may need to travel
a considerable distance for treatment.
How the intervention might work
Axillary treatment can eliminate residual disease in the ax-
illa, decrease axillary recurrence and, perhaps, improve
overall survival by improving local control. One breast can-
cer death out of four local recurrences can be prevented
over the 15 year period [5]. ANC provides information on
the number of positive nodes (extent of nodal involvement)
and this may influence adjuvant systemic therapy and
radiotherapy decisions.
Axillary recurrence rates following ANC or ART have
been reported to be as low as 1 or 2%, however, both are
associated with significant long term problems such as pain,
arm swelling (lymphedema), restricted shoulder movement,
and sensory changes in the arm and hand (for example,
numbness) [4,6-8].
Why it is important to perform this review
The value of axillary treatment in the era of early detection,
small tumors and adjuvant systemic therapy may be more
limited than in the past. Less than 50% of patients with sen-
tinel node metastases are found to have additional nodal
disease at the second operation, ANC [9]. Once axillary
node metastases are defined by information for systemic ad-
juvant therapy is adequate without the need for harvesting
more nodes, since systemic therapies are not usually gov-
erned by the number of node metastases [10]. Most patients
receive adjuvant systemic therapy and we now have molecu-
lar determinants of prognosis and predictors of treatment
benefit. Moreover, the lower axilla is treated inadvertently in
all patients as it is included in the irradiation field during
whole breast radiotherapy, or some lower level axillary
nodes are included in the mastectomy specimen [11].
Physicians are at a crossroad in terms of effective axil-
lary treatment with the Z0011 trial [12] suggesting a ‘de-
escalation’ of nodal therapy, but there are some concerns
about this approach as suggested by the MA20 trial [13].
This has led us to review existing evidence to address
the prevailing uncertainty, as the harms of axillary treat-
ment may outweigh the benefits if the risk of axillary re-
currence is low.
Objectives
To assess the short and long term benefits and adverse
effects of axillary treatment (axillary lymph node clearance
or axillary radiotherapy) for patients with lymph node
positive early-stage breast cancer.
Methods
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized clinical trials evaluat-
ing: 1) Axillary treatment (axillary lymph node clearance
or axillary radiotherapy) versus no axillary treatment; 2)
Axillary lymph node clearance versus axillary radiotherapy.
Types of participants
Patients with clinically node negative early-stage invasive
breast cancer and positive axillary lymph nodes on axil-
lary dissection, axillary sampling or sentinel node biopsy,
regardless of primary treatment for breast cancer. Both
mastectomy and breast conservation patients will be
included. Early breast cancer includes tumors classified as
AJCC stage I to IIIA. We will exclude women who have
had previous surgical treatment for the current tumor and
those with a history of breast cancer. We will not exclude
patients based on age, race or histological type.
Types of intervention
Axillary treatment (axillary lymph node clearance or ax-
illary radiotherapy).
Types of outcome measures
In this review, where possible, we will extract data at 5,
10, 15, 20 and 25 years.
Primary outcomes
1. Axillary (Regional) recurrence: defined as tumor
recurrence in lymph nodes draining the primary
tumor site, namely, nodes in the ipsilateral axilla,
infraclavicular fossa, supraclavicular fossa and
interpectoral area.
2. Disease-free survival: defined as the interval between
the date of breast cancer diagnosis and the date of
the first loco-regional or systemic recurrence, or date
of death, whichever comes first.
3. Overall survival: defined as the interval from the date
of breast cancer diagnosis until the date of death
from any cause.
Secondary outcomes
1. Breast/chest wall (Local) recurrence: this includes
recurrence after mastectomy in the skin or soft tissue
of the chest wall, or within the treated breast
following breast conservation.
2. Distant metastasis: all other sites of recurrence are
included under this heading and are classified as:
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soft-tissue category, visceral category, central nervous
system and skeletal spread.
3. Time to axillary recurrence: the time between the
date of breast cancer diagnosis and the date of first
sign of axillary recurrence.
4. Axillary recurrence-free survival: the time interval
between the date of diagnosis and the date of first
sign of axillary recurrence without evidence of
distant disease, or date of death, whichever comes
first.
5. Arm morbidity: which includes lymphedema,
shoulder stiffness, paresthesia, pain, loss of functional
capacity, winging of scapula and wound contracture
or scarring problems. Where any grading systems are
used for the severity of these complications, scores
will be recorded.
6. Quality of life (using trial-specific instruments).
7. Health economic costs.
Search methods for identification of studies
Electronic searches
We will search the following databases.
(a) The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, current issue).
See Appendix 1.
(b) MEDLINE (via OVID) (from January 1980 until the
search date). See Appendix 2.
(c) EMBASE (via OVID) (from January 1980 until the
search date). See Appendix 3.
(d) The WHO International Clinical Trials Registry
Platform (ICTRP) search portal (http://apps.who.
int/trialsearch/) for all prospectively registered and
ongoing trials. See Appendix 4.
We will not apply search restrictions to age, race, tumor
size or histological type. We will not impose any language
restrictions.
Searching other resources
References from published studies
We will check reference lists from eligible trials selected
by electronic searching to identify further relevant trials.
Conference proceedings
We will search the American Society of Clinical Oncol-
ogy and San Antonio Breast Cancer Symposium confer-
ence proceedings.
Unpublished literature (electronic)
We will search the UK Clinical Trials Gateway (UKCTG)
and the National Institute for Health Research Clinical
Research Network (NIHR CRN) Portfolio database for
details of ongoing trials in the UK.
Personal communication
We will contact, by e-mail, the corresponding authors for
missing data that are needed for the systematic review.
Data collection and analysis
Selection of studies
Two authors will independently scan the title, abstract and
keywords of every record identified by the search. We will
assess the full articles if the information given suggests
that the study may conform to our criteria. We will resolve
differences in assessment by discussion and, in cases of
disagreement, we will consult another review author.
Data extraction and management
Two authors will perform data extraction independently
using a standard form, and we will resolve disagreements
by discussion. We will enter data on outcome measures
into Review Manager 5.1 (RevMan 2011) software for
analysis. Where possible, we will extract data on tumor
and patient characteristics, size of nodal metastasis, sur-
gery performed and adjuvant treatments.
Assessment of risk of bias in included studies
Two review authors will independently assess the quality
and risk of bias of the eligible studies using the
Cochrane Collaboration’s risk of bias tool [14]. Any dis-
agreements will be resolved by discussion or by involv-
ing a third assessor.
Sequence generation (checking for possible selection
bias) We will describe for each included study, the
methods used to generate the allocation sequence. The
methods will be assessed as:
 low risk of bias (any truly random process, for
example, random number table; computer random
number generator),
 high risk of bias (any non-random process, for
example, odd or even date of birth; hospital or clinic
record number) or,
 unclear risk of bias.
Allocation concealment (checking for possible selection
bias) We will assess whether intervention allocation
could have been foreseen in advance of, or during re-
cruitment, or changed after recruitment:
 low risk of bias (for example, telephone or central
randomization; consecutively numbered, sealed
opaque envelopes);
 high risk of bias (open random allocation; unsealed
or non-opaque envelopes, alternation; date of birth)
or,
 unclear risk of bias.
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Blinding (checking for possible performance bias)
Given the nature of the interventions being evaluated,
blinding of either the care providers or the patients re-
ceiving care was not feasible. We will assess methods
used to blind outcome assessment as:
 low, high or unclear risk of bias for participants;
 low, high or unclear risk of bias for personnel.
Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We will indicate for each included study, the completeness
of outcome data for each main outcome, including attrition
and exclusions from the analysis. We will state the number
lost to follow-up (compared with the total randomized par-
ticipants), reasons for attrition/exclusion where reported,
and any re-inclusions in analyses which we undertake.
We will assess methods as:
 low risk of bias (for example, no missing outcome
data; missing outcome data balanced across groups);
 high risk of bias (for example, numbers or reasons
for missing data imbalanced across groups; ‘as
treated’ analysis done with substantial departure of
intervention received from that assigned at
randomization) or,
 unclear risk of bias.
Selective reporting bias and other sources of bias We
will describe for each included study how we investi-
gated the possibility of selective outcome reporting bias
and what we found. We will assess the methods as:
 low risk of bias (where it is clear that all of the
study’s pre-specified outcomes and all expected
outcomes of interest to the review have been
reported);
 high risk of bias (where not all the study’s pre-
specified outcomes have been reported; one or more
reported primary outcomes were not pre-specified;
outcomes of interest are reported incompletely and
so cannot be used; study fails to include results of a
key outcome that would have been expected to have
been reported) or,
 unclear risk of bias.
Other bias We will describe for each included study,
any important concerns we have about other possible
sources of bias. We will assess whether each study is free
of other problems that could put it at risk of bias:
 low risk of other bias;
 high risk of other bias or,
 unclear whether there is risk of other bias.
Overall risk of bias We will make explicit judgements
about risk of bias for important outcomes both within
and across studies. With reference to (1) to (6) above,
we will assess the likely magnitude and direction of the
bias and whether we consider it likely to impact on the
findings. We plan to explore the impact of the level of
bias through undertaking sensitivity analyses; temporar-
ily removing those studies at high risk of bias from the
meta-analysis to see what impact this will have on the
treatment effect.
Measures of treatment effect
We will carry out statistical analysis using Review Manager
5.1 (RevMan 2011). We will use fixed-effect meta-analysis
for combining data in the absence of heterogeneity. For
those outcomes where there are moderate or high levels of
heterogeneity, where clinically meaningful, we will use
random-effects analysis and these results will be presented
as average treatment effects.
For dichotomous data, we will present results as sum-
mary risk ratio (RR) with 95% confidence intervals. For
continuous data, we will use the mean difference if out-
comes were measured in the same way between trials.
We will use the standardized mean difference to com-
bine trials that measured the same outcome, but using
different methods. If there is evidence in the trials of ab-
normally distributed data, we will report this.
Unit of analysis issues
We anticipate that we will only find trials in which the unit
of randomization was the individual patient. However, if we
find cluster randomization trials they will be included.
Dealing with missing data
For included studies, we will note levels of attrition in the
risk of bias tables. We plan to explore the impact of in-
cluding studies with high levels of missing data in the
overall assessment of treatment effect by using sensitivity
analysis. Where possible we will analyse all cases accord-
ing to randomization group, irrespective of whether or not
study participants received the intended intervention.
Assessment of heterogeneity
We will examine heterogeneity between the trials by visu-
ally examining the forest plots to judge whether there are
any apparent differences in the direction or size of the
treatment effect between studies. We will also consider the
I-squared and T-squared statistics and the P-value of the
Chi-squared test for heterogeneity. If we identify hetero-
geneity among the trials (if the value of I-squared is greater
than 30%, and the value of T-squared is greater than zero
or the P-value of the Chi-squared test for heterogeneity is
greater than 0.1), we will explore it by pre-specified sub-
group analysis and by performing sensitivity analysis.
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Assessment of reporting biases
We will not formally assess reporting bias; without access
to study protocols it is difficult to know whether or not
there has been outcome-reporting bias. However, we will
note where we have any concerns about reporting bias (for
example, where key outcomes do not seem to be reported).
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it
using subgroup analyses and sensitivity analyses. We will
consider whether an overall summary is meaningful, and if
it is, we will use random-effects analysis to produce it. We
plan to carry out the following subgroup analyses:
1. Type of axillary treatment allocated at trial entry:
axillary lymph node clearance, axillary radiotherapy;
unknown or mixed.
2. Size of nodal metastasis in the sentinel node biopsy:
macrometastases (tumor deposit greater than 2.0 mm in
the largest dimension), micrometastases (greater than
0.2 mm and/or more than 200 cells in a single
histological cross-section, but none greater than 2 mm),
isolated tumor cells (small cluster of cells not greater
than 0.2 mm, or single tumor cells, or a cluster of fewer
than 200 cells in a single histological cross-section),
unknown or mixed.
3. Type of primary breast surgery: mastectomy,
lumpectomy, mixed or unknown.
4. Subgroup analyses will be restricted to the primary
outcomes.
For fixed-effect meta-analysis, we will carry out an inter-
action test to examine subgroup differences. For both
fixed- and random-effects meta-analysis, we will examine
the confidence intervals for subgroups; with overlapping
confidence intervals potentially suggesting no important
differences between subgroups.
Sensitivity analysis
We plan to include a sensitivity analysis based on tem-
porarily excluding trials that were not of high quality. If
this exclusion leads to a substantive difference in the
overall results, we will exclude quasi-random studies or
those with serious attrition. Only the primary outcomes
will be included in the sensitivity analysis.
Appendix 1
Search strategy: CENTRAL
#1. (breast cancer): ti,ab,kw in Trials
#2. MeSH descriptor Breast Neoplasms explode all trees
#3. (#1 or #2)
#4. (four node sampling): ti,ab,kw or
(4 node sampling): ti,ab,kw in Trials
#5. (axillary node dissection): ti,ab,kw or
(axillary node clearance): ti,ab,kw in Trials
#6. MeSH descriptor Lymph Node Excision explode
all trees
#7. MeSH descriptor Axilla explode all trees
#8. (#6 or #7)
#9. (#4 or #5 or #8)
#10. MeSH descriptor Radiotherapy explode all trees
#11. (#7 and #10)
#12. (#3 and #9 and #11)
#13. (randomised controlled trial):pt or
(randomized controlled trial): pt or (RCT): pt or
(randomised controlled trial): ti,ab,kw or
(randomized controlled trial): ti,ab,kw in Trials
#14. (#12 and #13)
Appendix 2
Search strategy: MEDLINE (OVID) 1980 – date of search
1. breast cancer.mp. or exp Breast Neoplasms/
2. four node sampling.mp.
3. 4 node sampling. ab,kw,ti.
4. axillary node dissection.mp.
5. axillary node clearance.mp.
6. exp Lymph Node Excision/
7. exp Axilla/
8. 6 and 7
9. 2 or 3 or 4 or 5 or 8
10. axillary radiotherapy.mp.
11. exp Radiotherapy/
12. 7 and 11
13. 10 or 12
14. randomised controlled trial.mp,pt.
15. randomized controlled trial.mp,pt.
16. RCT.mp,pt.
17. 14 or 15 or 16
18. 1 and 9 and 13 and 17
19. limit 18 to yr="1980 -Current"
Appendix 3
Search strategy: EMBASE (OVID) 1980 - date of search
1. breast cancer.mp. or exp breast cancer/
2. four node sampling.mp.
3. 4 node sampling.mp.
4. axillary node dissection.mp.
5. axillary node clearance.mp.
6. exp lymphadenectomy/
7. exp axilla/
8. 6 and 7
9. 2 or 3 or 4 or 5 or 8
10. axillary radiotherapy.mp.
11. exp radiotherapy/
12. 7 and 11
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13. 10 or 12
14. randomised controlled trial.mp,pt.
15. randomized controlled trial.mp,pt.
16. RCT.mp,pt.
17. 14 or 15 or 16
18. 1 and 9 and 13 and 17
Appendix 4
Search strategy: WHO ICTRP
Title: Breast cancer and axillary
AND
Condition: Breast cancer or breast neoplasm
AND
Intervention: Four node sampling or axillary dissection
or axillary clearance or axillary radiotherapy
Recruitment Status: All
Date of Registration: 01/01/1980 – search date.
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